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The role of pathology characteristics of breast cancers as prog-
nostic or predictive factors in management of breast cancer is
widely acknowledged with recent editions of one leading journal
devoted to this topic (Gasparini, 1998). The combination of histo-
logical features in the form of a single quantitative index of prog-
nosis has been used for a number of functions. These include
guidance on the type and extent of therapy, stratification for clin-
ical trials, informal monitoring of screening programmes, and in
the formal prediction of mortality differences in trials of screening
or prevention (Day and Duffy, 1996).
The Nottingham Prognostic Index (NPI) was derived from a
database of pathology and other characteristics (Haybittle et al,
1982), later assessed prospectively (Todd et al, 1987), and
extended (Galea et al, 1992) to cover over 1600 cases. Use of the
index in patients with symptomatic and operable disease has been
independently validated (Brown et al, 1993; Balslev et al, 1994).
However, although it is currently being used to predict mortality
differences between the two arms of the UK trial of mammo-
graphic screening frequency it has not been validated in a screened
population. The index relies on pathological size, axillary node
status and histological grade, with size included as a linear term. It
follows that each millimetre increase in size has the same effect on
the value of the index, which may not be logical in light of the
excess distribution of small cancers detected through screening.
The size groupings used in assessment of the Two Counties Breast
Screening Trial (Tabar et al, 1985) was distinctive at 1–9, 10–14,
15–19, 20–29, 30–49 and ³50 mm, taking account of this changed
distribution, may be more appropriate to the screening situation,
and have been used in this study.
In previous reports we have emphasized the importance of
histological special type as an independent determinant of survival
in symptomatic (Dixon et al, 1985) and screen detected cancers
(Anderson et al, 1986, 1991) and in this study the feature has been
included as an additional variable.
The present report uses data from breast cancers diagnosed in
women invited to participate in the Edinburgh Randomized Trial
(ERT) of breast cancer screening. Such cancers have been system-
atically ascertained through a follow-up period of up to 14 years
from the date of recruitment (1978–1985) and the outcome of
mortality benefit reported (Alexander et al, 1999). The objective
of this study was to identify criteria for inclusion in an optimal
prognostic/predictive index for use in populations of screened
women that might also be applicable to predicting mortality in
screening trials.
METHODS
Study population
The composition of the study population, the screening procedure,
and the establishment of a pathology register have been described
previously (Roberts et al, 1984). The women were invited for
annual physical examination and biennial mammography over a
period of time which depended on their year of randomization (8
years for those randomized 1978–81, 6 years for those in 1982–3,
and 4 years for those in 1984–5). This period of intervention ended
for all entrants around 1988 when NHS service screening became
available to all women aged under 65 years. Breast cancers diag-
nosed up to 10 years from entry to the trial are included in the
present analysis.
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Entry to the database of pathology information relating to size,
histological nature of cancers and lymph node status was through
completion of a standardized form (Roberts et al, 1984). Slides of
all cancers and axillary nodes were examined by two pathologists
(TJA, JL) during the trial field work, including those diagnosed in
other local pathology departments (Western General Hospital, St
John’s Hospital). In a few cases treated in distant hospitals, rele-
vant data were extracted from pathology reports (TJA). The
criteria for histological typing as ‘special type’ (ST) have been
described (Anderson et al, 1986, 1991; Page and Anderson, 1987)
and are in agreement with the National Coordinating Group
(1995). Combined histological grade of cancers was assessed
according to Elston and Ellis (1991) and criteria defined by the
National Coordinating Group (1995). This was completed by the
same pathologists (TJA, JL) in a separate review (blinded to detec-
tion method) of the relevant original slides. The consistency of
grading between the reviewers was established on a subset of 52
cancers double read, giving kappa value of 0.54.
The customary size categories for invasive breast cancers are
based on TNM (International Union Against Cancer, 1997) but in
reports of the Two Counties breast screening trial (Tabar et al,
1985, 1992) the discrimination points were based on mm diame-
ters less than 10, less than 15, and less than 20. In the present study
we have considered 6 size categories (sizegroup), as 1 = 1–9, 2 =
10–14, 3 = 15–19, 4 = 20–29, 5 = 30–49 and 6 = ³50 mm, as used
by others (Day et al, 1989; Duffy et al, 1991), and are an alterna-
tive to measured size expressed as a linear variable, as used in NPI.
The majority of patients had axillary node status determined by a
node sample, which in the Edinburgh Breast Unit requires the
removal of 4 nodes from the lower axillary fat contiguous with the
axillary tail of the breast (Steele et al, 1985; Forrest et al, 1995).
However, in general surgical practice both fewer or more nodes
may be removed during the procedure. A smaller number of
women had a total node dissection of all three levels of the axilla,
which clearly provides a larger number of nodes for examination.
On the standard record form the number of positive and negative
nodes examined pathologically were separately entered, allowing
the total number removed to be ascertained. We considered
limiting information concerning the number of involved axillary
nodes to examples with 4 or more nodes removed, but elected to
include all dissections. We appreciate the limitations of a sampling
procedure to determine the actual number of positive nodes, but
this represents surgical practice as audited in Scotland (Scottish
Cancer Therapy Network, 1996) and likely to be performed else-
where in UK. In this paper ‘node status’ is either positive or nega-
tive, and ‘node group’ defines positivity as 1 = none, 2 = 1–3 and
3 = 4 or more involved.
The Nottingham Prognostic Index (= 0.2 ´ size [cm] + grade
[1–3] + nodes [1–3], where 1 = node negative, 2 = 1–3 nodes posi-
tive, and 3 = >3 nodes or the apical node positive) was calculated
from the available information. We have ignored information on
apical node status, which was available only when an axillary clear-
ance was performed. This formulation of axillary node information
is suggested as a modification (Galea et al, 1992) of the original
triple biopsy used in Nottingham, to conform with usual surgical
practice; the NPI is now compiled from a sampling procedure
similar to that in Edinburgh. In order to estimate the NPI where data
was missing, multiple regression analysis was applied to the data
set for which all the data was known; the dependent variable was
the NPI and the independent variables were successive combina-
tions of two and of one of the pathological characteristics. When
detection group (see below) improved the model significantly it
was included. This procedure yielded regression equations from
which the NPI could be estimated for cases with missing data.
Statistics
The cases forming the group for detailed study were those classi-
fied as operable invasive (i.e. lacking indication at diagnosis of
being locally advanced and/or metastatic) and for whom at least
one of the following characteristics was entered on the database:
• pathology size
• histological type
• combined histological grade
• node status and number positive.
Cox’s proportional hazards method (Cox, 1972) was applied to
investigate the relationship of pathology characteristics to the
survival of cases from the time of diagnosis. Survival was
censored if breast cancer was neither the underlying nor a contrib-
utory cause of death and censoring was applied at 14 years from
trial entry date (or earlier in the case of women who entered the
trial 1982–85 (see Alexander et al, 1999)). Since lead time bias
and length biased sampling influence the survival from the time of
diagnosis of screen-detected cancers, all cancers have been placed
in one of four ‘detection groups’; (i) prevalence (first) screen; 
(ii) incident (later) screen; (iii) interval cases and (iv) others.
Adjustment for those detection groups has been applied systemati-
cally in the analyses.
Except where an alternative has been stated, all analyses of
pathological size consider linear trend across six groups (size-
group, see above), all of grade and node trend across three groups.
RESULTS
Population distribution of breast cancer severity
The distribution of 1029 cancers accumulated in the study,
according to severity of disease state, as either in-situ, invasive
operable or non-operable at diagnosis, is shown in Table 1. The
two notable features are the excess of cancers in the screened
population (55.7%), and the major proportion of inoperable
cancers in the control population (36.8%), almost double that in
those offered screening. The following analyses are restricted to
691 operable cases for which at least one item from the pathology
data-set (size, type, grade, node positivity) was available. Several
analyses are restricted to 458 cases for whom all of these were
known. Of the 691 cases, 116 were from prevalence screen, 163 at
incident screen, 64 were interval cases and 348 were ‘other’ detec-
tions (including those of the control arm of the trial).
Interrelationships of size with histological type, grade
and node positivity
As is shown in Figure 1 there are clear cut trends for higher grade
with increasing size (expressed in six categories), and a similar
trend is present for proportion by node group in Figure 2 
(P < 0.001). A linear relationship with special histological type is
less evident (Figure 3).
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These analyses were restricted to the 672 cases for whom patho-
logical size was known. Size was entered into the Cox regression
model in two ways: (i) as actual size so that the model considered
the linear effect of size and (ii) as the sizegroups described above.
The addition of actual size as a linear trend to a model containing
sizegroup was without effect (hazard ratio [HR] = 1.00, 95% CI
0.96–1.03 with adjustment for detection node group, and
0.97–1.03 without). On the other hand, when sizegroup was added
to a model containing actual size, the HRs were 1.67 and 1.71 with
95% CI of 1.19–2.35 and 1.22–2.39, with and without adjustment
for nodegroup respectively. The P values for inclusion of the extra
terms in the model were 0.002 and 0.001. These data demonstrate
that the use of the chosen six sizegroups is significantly more
effective as a prognostic indicator than actual sizes expressed as a
linear trend. The use of log (actual size + 0.5) was evaluated and
was only slightly less effective than sizegroup.
Univariate analysis of pathology characteristics
Univariate analysis of relevance for each pathological character-
istic against survival, with size entered in six categories, grade as
one of three classes, histological type as ‘special’ or ‘not special’,
and node as status or group shows each to be highly significant
(Table 2). The table also shows the number of cases for which each
characteristic was available.
Performance of the NPI
In these data the NPI is significantly associated with survival with
and without adjustment for detection group (HR = 1.86, CI:
1.63–2.13; HR = 1.82, CI: 1.59–2.01, P < 0.001). However both
size group and histological type, individually and in combination,
make a further significant contribution to the survival model
(Table 3). When considered by trial arm (Table 4), it is clear that
the independent additional effect of size group applies particularly
to the screening arm.
Multivariate analysis of the Edinburgh data
When the pathology characteristics were tested in multivariate
analysis, after adjustment for the others, they all contributed with
independent significance (Table 5). Coefficients to apply in an
index of prognosis are given in the table. These refer to the 691
operable cases, but similar results are given by the 458 with all
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Figure 1 Percentage distribution of invasive cancer grades within each of
the incremental size categories
Figure 2 Proportion of special type invasive cancers within each of the
incremental size categories
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Figure 3 Percentage distribution of node positive status (and number
category) within each of the incremental size categories
Table 1 ERT cancers1 by severity
Trial Arm Non-inv Invasive Advanced or Total
Micro-inv Operable Mets
Screening 50 (8.7) 416 (72.6) 107 (19.7) 573 (100)
Control 13 (2.9) 275 (60.3) 168 (36.8) 456 (100)
1Number and (percentage)490 TJ Anderson et al
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Figure 4 Breast cancer survival curves of screened women divided into
four groups (of equal numbers) according to Nottingham prognostic index
(NOTCAT)
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Figure 5 Breast cancer survival curves of screened women divided into
four groups (of equal numbers) according to the new index (EDCAT)
Table 2 Univariate analyses1 of pathology indicators
Pathology Indicator Number HR CI P-value
Size group 672 1.67 1.44 – 1.93 <0.001
Histological type 631 2.96 1.85 – 4.74 <0.001
Grade 586 2.37 1.80 – 3.11 <0.001
Node status 629 2.99 2.08 – 4.29 <0.001
Node group 629 2.19 1.75 – 2.73 <0.001
1Analyses adjusted for detection group using Cox proportional hazard
method.
Table 3 Independent effect of pathology indicators after NPI adjustment
Indicator1 Cases HR CI P-value
Size group 672 1.31 1.11 – 1.55 0.001
Histological type 583 1.81 1.10 – 2.94 0.015
Grade 586 1.26 0.87 – 1.83 0.21
Node group 629 0.91 0.63 – 1.39 0.5
Size group
Histological type
574
1.31 1.10 – 1.56
<0.001 1.92 1.16 – 3.17
1Adjusted for detection group.
Table 4 Independent effect of pathology indicators after NPI in each trial arm
Screening Arm Control Arm
HR CI P HR CI P
Size group 1.40 1.12 – 1.75 0.003 1.22 0.95 – 1.57 0.11
Histological type 1.69 0.91 – 3.15 0.08 2.02 0.89 – 4.58 0.07
Size group 1.42 1.12 – 1.79
0.003
1.17 0.91 – 1.52
0.07 Histological type 1.85 0.99 – 3.46 2.17 0.90 – 5.22
1All analyses of the screening arm adjust for cancer diagnosis group and NPI; all analyses of the control arm adjust
for NPI.
2Analyses use all available data (ie all subjects with NPI and relevant additional indicators known).
Table 5 Multivariate analysis and coefficients of the pathology indicators
b SE(b)H R C I P 1
Size group2 0.36 0.081 (1.43) (1.19 – 1.71) <0.001
Node group3 0.54 0.12 (1.97) (1.31 – 2.96) <0.001
Grade 0.53 0.15 (1.74) (1.24 – 2.46) <0.001
Histological type 0.56 0.26 (1.68) (0.93 – 3.04) 0.028
1For inclusion in the model in addition to all others in the Table
2Linear trends across the size groups: 1-9, 10-14, 15-19, 20-29, 30-49, 50+ mm.
3Linear trends across the three groups: 1=N neg., 2=1-3 N pos., 3= >3 N pos.
4Simplified index formula = 0.7 x size group + 1 x type + 1 x grade + 1 x node group.data known. Applications of this index in comparisons with the
NPI are shown in Figures 4 and 5. These figures are for screened
women (i.e. prevalence screen detected, incidence screen detected
and interval cases) and split cases into approximately four equal
size groups for both NPI and the new index (NOTCAT, EDCAT).
When analyses were restricted to small cancers (<10 and 10–
14 mm) the formula gave significant discrimination of benefit for
10–14 mm (HR 5.41, CI 1.77–16.58, P = 0.008) but this was
absent for cancers <10 mm alone.
DISCUSSION
The pathological features of breast cancers in the two arms of the
trial establish that screening in Edinburgh have two major effects.
Firstly, the proportion of advanced or inoperable cases is almost
halved, and secondly there is improvement in the proportion of
invasive cancers of smaller size and node negative (Anderson et al,
1986, 1991). Both differences are acknowledged screening effects
(Day et al, 1989) but the component of the mortality reduction
attributable to each cannot be determined. Swedish studies report
only a 10% proportion of advanced/inoperable disease (Frisell et
al, 1987; Andersson et al, 1988) and allowance may need to be
made for this fact in comparing screening effect between coun-
tries. However, the reductions in mortality at 14 years achieved in
the ERT of 29% with censoring 3 years from end of trial field work
(Alexander et al, 1999) are equivalent to those achieved in Sweden
(Nystrom et al, 1993).
Breast cancer pathological features have also become accepted
for inclusion into single indices, such as NPI, that in turn have
allowed case classification into a small number (3–5) of separate
prognostic categories. These may be put to different uses, but some
relevant factors must first be acknowledged. The categories may be
chosen to be of approximately equal numbers (as here) or selected
by statistical criteria. If the latter, the choice of cut-point between
two groups (good/poor prognosis) that minimizes the P value for
the comparisons between them (Altman et al, 1994; Sauerbrei et al,
1997) may over-estimate the effect (Beuttner et al, 1997);
conversely, the equal numbers method ignores important data. It is
pertinent that biostatisticians have used prognostic indices to
predict future mortality for cases arising in randomized control
trials of primary/secondary prevention (Day and Duffy, 1996) and
that such predictions have smaller variance than observed
mortality. It is thus essential that optimal use is made of prognostic
data available at diagnosis. In this regard, the NPI has been used as
the basis for comparisons of predicted mortality in women screened
every three years or annually. Differences between cancers at the
two intervals were small and did not achieve statistical significance
(Duffy, personal communication). The current analysis has demon-
strated that significant improvements are likely to be gained in the
ability of pathology characteristics of operable invasive breast
cancers to act as predictors for this outcome (surrogates) if they are
entered according to particular size categories, as histological
special type or not, by grade and also grouping by number of nodes
with metastasis grouped as for the NPI.
The finding that the NPI, a widely accepted and clinically used
measure to help determine therapy options, needs important modi-
fication to give optimal explanation of survival differences experi-
enced with mammographic screening requires comment. It is clear
that the effect of size is not linear, and that the regression coeffi-
cient employed in the NPI is not optimal for a population that
contains a substantial proportion of mammographic screen-
detected cases. A recent report of a Swedish population from 5
hospitals with similar characteristics also doubted the simple rela-
tionship with size (Sundquist et al, 1999). They used three size
categories (≤10, 11–20, > 20 mm) and developed different factor
coefficients, but endorsed the ‘…use of grade and the NPI in order
to increase the comparability of groups of patients receiving
different therapies’. It is therefore important to stress that the size
groups chosen here give distinction between groups at all levels
for grade and node groups (Figures 1, 2). The difference between
categories 1 and 2, whilst only a few mm appears to be as impor-
tant as that between 3 and 4 and 4 and 5.
The relevance of identifying special type cancers is accentuated
in breast screening (Anderson et al, 1986, 1991; Tabar et al, 1996),
on account of differing frequencies from symptomatic cases.
Histological special type should not be interpreted as a ‘competi-
tive’ factor to contrast with grade (Pereira et al, 1995). The two
assessments are complementary in the sense that classical special
type carries an importance for survival that is separable from
grade. It is also likely that both histological type and grade are
needed to interpret the natural history of breast cancer. Our data
indicate a drift between size group, with larger size giving worse
grade, and possibly more node spread and fewer special type.
These issues have recently been discussed by Tabar et al (1999)
and Anderson et al (2000).
The present findings indicate the need for re-evaluation of the
pathology criteria used to measure screening effect, whether of
trials or of service screening, as in the UK programmes. This
applies both to use as surrogates of mortality benefit prediction or
for setting targets for performance audit. This has particular rele-
vance because of comments on outcome prediction for cancers
<15 mm (Tabar et al, 2000). Our findings indicate that the avail-
able features discriminate well for cancers 10–14 mm, but confirm
the need for supplementary data to identify the few cases with poor
outcome in cancers <10 mm. We cannot address the question
whether this is best achieved from additional pathology or
radiology features. However, from an assessment of the ERT data
base, the current data (potentially) available from UK screening
pathology forms would be most informative when included as
invasive cancer size in six categories and histological type as
special or not, with histological grade and node metastasis in three
groups each. A proposal for a formula is appended below Table 5.
It is crucial to validate this model on an independent set of
screening results with dedicated follow-up. It is hoped that one or
other of the UK Trials set up to answer questions of mammo-
graphic screening feasibility, in terms of frequency, number of
views or age at invitation, will provide the necessary data.
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